2.82

2.08% -0.06

After Hours: 2.75 -0.07 -2.48%

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $2.82, with a volume of 167.08K. It is down -2.08% in the last 24 hours and down -9.62% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Previous Close:

$2.88

Open:

$2.88

24h Volume:

167.08K

Relative Volume:

0.36

Market Cap:

$219.07M

Revenue:

Net Income/Loss:

$-29.07M

P/E Ratio:

-9.0968

EPS:

-0.31

Net Cash Flow:

$-31.85M

1W Performance:

+1.81%

1M Performance:

-9.62%

6M Performance:

+12.80%

1Y Performance:

+158.72%

1-Day Range:

$2.80

$2.92

1-Week Range:

$2.66

$3.03

52-Week Range:

$0.98

$4.00

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2024-11-06

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	2.82	219.07M	0	-29.07M	-31.85M	-0.31
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

Nov 22, 2024

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program - GuruFocus.com

Nov 22, 2024

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Trevi Therapeutics to Present Haduvio Development at Piper Sandler Healthcare Conference | TRVI Stock News - StockTitan

Nov 21, 2024

Nov 16, 2024

Trevi Therapeutics to Participate in Upcoming April Events - GuruFocus.com

Nov 16, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages - Defense World

Nov 16, 2024

Nov 14, 2024

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow

Nov 14, 2024

Nov 13, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Average PT from Brokerages - MarketBeat

Nov 13, 2024

Nov 12, 2024

How Do Things Look For Trevi Therapeutics Inc (NASDAQ: TRVI) In The Short-Term? - Stocks Register

Nov 12, 2024

Trevi Therapeutics Announces Proposed Public Offering - Quantisnow

Nov 12, 2024

Trevi Therapeutics to Participate in Upcoming September Events - Quantisnow

Nov 12, 2024

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Quantisnow

Nov 12, 2024

Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences - Quantisnow

Nov 12, 2024

Nov 11, 2024

FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - MarketBeat

Nov 11, 2024

Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings - Defense World

Nov 11, 2024

Nov 08, 2024

Earnings call: Trevi Therapeutics reports Q3 2024 financials, clinical updates - Investing.com

Nov 08, 2024

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Nov 08, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Earnings call: Trevi Therapeutics reports Q3 2024 financials, clinical updates By Investing.com - Investing.com UK

Nov 08, 2024

Nov 07, 2024